BAIULA, MONICA
 Distribuzione geografica
Continente #
AS - Asia 4.491
NA - Nord America 4.489
EU - Europa 3.720
AF - Africa 475
SA - Sud America 258
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 13.444
Nazione #
US - Stati Uniti d'America 4.433
SG - Singapore 1.265
CN - Cina 1.212
VN - Vietnam 1.053
IT - Italia 1.048
GB - Regno Unito 795
DE - Germania 457
HK - Hong Kong 294
FR - Francia 257
IN - India 214
SE - Svezia 211
RU - Federazione Russa 187
TG - Togo 171
BR - Brasile 170
IE - Irlanda 160
UA - Ucraina 137
CI - Costa d'Avorio 123
NL - Olanda 114
JP - Giappone 84
KR - Corea 83
FI - Finlandia 79
ZA - Sudafrica 76
BG - Bulgaria 68
JO - Giordania 49
EE - Estonia 47
SC - Seychelles 46
CA - Canada 42
ID - Indonesia 34
NG - Nigeria 34
AR - Argentina 32
PH - Filippine 29
HR - Croazia 24
TR - Turchia 23
BD - Bangladesh 21
CH - Svizzera 21
TH - Thailandia 21
BE - Belgio 20
PK - Pakistan 20
ES - Italia 19
IQ - Iraq 18
PL - Polonia 17
AT - Austria 16
CL - Cile 13
TW - Taiwan 12
IR - Iran 10
PE - Perù 10
SA - Arabia Saudita 10
EC - Ecuador 9
MX - Messico 9
PT - Portogallo 9
RO - Romania 9
MY - Malesia 8
AU - Australia 7
CO - Colombia 7
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
IL - Israele 5
LB - Libano 5
PY - Paraguay 5
UZ - Uzbekistan 5
EG - Egitto 4
ET - Etiopia 4
LT - Lituania 4
MA - Marocco 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HU - Ungheria 3
SI - Slovenia 3
TN - Tunisia 3
UY - Uruguay 3
AO - Angola 2
DZ - Algeria 2
EU - Europa 2
GY - Guiana 2
KE - Kenya 2
LK - Sri Lanka 2
MD - Moldavia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
AM - Armenia 1
AZ - Azerbaigian 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
GE - Georgia 1
GF - Guiana Francese 1
JM - Giamaica 1
KH - Cambogia 1
LU - Lussemburgo 1
LY - Libia 1
MM - Myanmar 1
MW - Malawi 1
OM - Oman 1
PS - Palestinian Territory 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 13.444
Città #
Singapore 861
Southend 665
Ashburn 417
Fairfield 373
Chandler 368
Bologna 361
Santa Clara 300
San Jose 289
Hong Kong 275
Ho Chi Minh City 270
Hanoi 217
Lomé 171
Princeton 167
Hefei 157
Wilmington 155
Beijing 154
Houston 150
Dublin 148
Seattle 147
Woodbridge 141
Cambridge 126
Abidjan 123
Ann Arbor 106
Lauterbourg 97
Boardman 96
Dong Ket 85
Nanjing 79
Dallas 74
Jacksonville 73
Council Bluffs 72
Milan 71
Tokyo 71
Westminster 69
Sofia 68
Seoul 63
Los Angeles 62
Helsinki 60
Frankfurt am Main 57
Padova 56
Berlin 51
Amman 49
Saint Petersburg 44
New York 43
Shanghai 42
Bremen 36
Medford 36
Da Nang 35
Redondo Beach 34
Jinan 33
Redmond 33
Shenyang 33
Buffalo 32
Hebei 31
San Diego 31
Abeokuta 30
Turin 30
Nanchang 28
Munich 27
Haiphong 26
Guangzhou 24
Jakarta 24
Zhengzhou 24
Tianjin 23
Biên Hòa 20
Des Moines 20
Falls Church 20
Rome 20
São Paulo 20
Redwood City 18
Changsha 16
Chicago 16
Modena 16
Bengaluru 15
Brussels 15
Denver 15
Hangzhou 15
Mülheim 15
Norwalk 15
Toronto 15
Jiaxing 14
Johannesburg 14
London 14
Nuremberg 14
Olalla 14
Forlì 13
Haikou 13
Shenzhen 13
Yubileyny 13
Bern 11
Bühl 11
Can Tho 11
Falkenstein 11
Quận Bình Thạnh 11
Bangkok 10
Hyderabad 10
Hải Dương 10
Istanbul 10
Kunming 10
Phoenix 10
Shijiazhuang 10
Totale 8.611
Nome #
Targeting integrins αvβ3 and α5β1 with new β-lactam derivatives 292
Synthesis and Biological Evaluation of Nonpeptide alpha-v-beta-3/alpha-5-beta-1 Integrin Dual Antagonists containing 5,6-Dihydropyridin-2-one Scaffolds 268
Can integrin agonists have cards to play against cancer? A literature survey of small molecules integrin activators. 268
Leukocyte Integrin Antagonists as a Novel Option to Treat Dry Age-Related Macular Degeneration 268
Dehydro-beta-proline Containing Alpha-4-beta-1 Integrin Antagonists: Stereochemical Recognition in Ligand-Receptor Interplay 263
Could Dissecting the Molecular Framework of β-Lactam Integrin Ligands Enhance Selectivity? 243
Chiral β-lactam-based integrin ligands through Lipase-catalysed kinetic resolution and their enantioselective receptor response 239
CSF tau is associated with impaired cortical plasticity, cognitive decline and astrocyte survival only in APOE4-positive Alzheimer's disease 238
5-aminomethyloxazolidine-2,4-dione hybrid α/β-dipeptide scaffolds as inductors of constrained conformations: Applications to the synthesis of integrin antagonists 232
New β-Lactam Derivatives Modulate Cell Adhesion and Signaling Mediated by RGD-Binding and Leukocyte Integrins 228
Nociceptin/orphanin FQ antagonizes lipopolysaccharide-stimulated proliferation, migration and inflammatory signaling in human glioblastoma U87 cells 228
α-linolenic acid-valproic acid conjugates: Toward single-molecule polypharmacology for multiple sclerosis 221
DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs 217
Therapeutic Targeting of Eosinophil Adhesion and Accumulation in Allergic Conjunctivitis 215
Conjecturing about Small-Molecule Agonists and Antagonists of α4β1 Integrin: From Mechanistic Insight to Potential Therapeutic Applications 214
β-Arrestin 2-mediated heterologous desensitization of IGF-IR by prolonged exposure of SH-SY5Y neuroblastoma cells to a mu opioid agonist 213
REST is up-regulated by epidermal growth factor in HeLa cells and inhibits apoptosis by influencing histone H3 acetylation 207
Transcription factor REST negatively influences the protein kinase C-dependent up-regulation of human mu-opioid receptor gene transcription 204
Functional Selectivity and Antinociceptive Effects of a Novel KOPr Agonist 201
Antiangiogenic Effect of Dual/Selective α5β1/αvβ3 Integrin Antagonists Designed on Partially Modified Retro-Inverso Cyclotetrapeptide Mimetics 197
The Bacterial Toxin CNF1 Protects Human Neuroblastoma SH-SY5Y Cells against 6-Hydroxydopamine-Induced Cell Damage: The Hypothesis of CNF1-Promoted Autophagy as an Antioxidant Strategy 197
Integrin-mediated adhesive properties of neutrophils are reduced by hyperbaric oxygen therapy in patients with chronic non-healing wound 191
Design of α/β-hybrid peptide ligands of α4β1 integrin equipped with a linkable side chain for chemoselective biofunctionalization of microstructured materials 191
Agonist-Regulated Internalization and desensitization of the Human Nociceptin Receptor Expressed in CHO Cells 183
Expression of the repressor element-1 silencing transcription factor (REST) is influenced by insulin-like growth factor-I in differentiating human neuroblastoma cells. 181
Synthesis and assay of retro-α4β1 integrin-targeting motifs 181
Modulation of αvβ3- and α5β1-integrin-mediated adhesion by dehydro-β-amino acids containing peptidomimetics 179
Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine 172
Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist 170
Phase II drugs under investigation for allergic conjunctivitis 170
Agonist-regulated endocytosis and desensitization of the human nociceptin receptor 163
NEW PEPTIDOMIMETIC α4β1-INTEGRIN ANTAGONISTS FOR REDUCING INFLAMMATION AND ALLERGIC REACTIONS 163
Identification of c[D-Trp-Phe-β-Ala-β-Ala], the First κ-Opioid Receptor-Specific Negative Allosteric Modulator 162
Role of nociceptin/orphanin FQ in thermoregulation 162
Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. 161
Prodynorphin-derived peptides 159
New coumarin-based anti-inflammatory drug: putative antagonist of the integrins alpha(L)beta(2) and alpha(M)beta(2). 158
Selective detection of α4β1 integrin (VLA-4)-expressing cells using peptide-functionalized nanostructured materials mimicking endothelial surfaces adjacent to inflammatory sites 158
Development of new beta-lactam-based integrin ligands: Synthesis and Applications 157
Development of isoxazoline-containing peptidomimetics as dual alpha-v-beta-3 and alpha-5-beta-1 integrin ligands. 156
Design, Pharmacological Characterization, and Molecular Docking of Minimalist Peptidomimetic Antagonists of α4β1 Integrin 155
Design and Pharmacological Characterization of α4β1 Integrin Cyclopeptide Agonists: Computational Investigation of Ligand Determinants for Agonism versus Antagonism 149
Dehydro-beta-amino acids as scaffolds for the preparation of alpha-v-beta-3, alpha-5-beta-1 and alpha-4-beta-1 integrin ligands 149
Design and synthesis of Alpha-v-beta-3 and Alpha-5-beta-1 integrin ligands as delivery systems for fluorescent molecules 148
TARGETING INTEGRINS WITH NEW BETA-LACTAM DERIVATIVES 146
Synthesis of Enantiomerically Pure alpha-v-beta-3 Integrin ligands Based on a 5,6-Dihydropyridin-2-one Scaffold. 145
Transcriptional activation of human mu-opioid receptor gene by insulin-like growth factor-I in neuronal cells is modulated by the transcription factor REST 144
Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis 139
Side chain effect in the modulation of αvβ3/α5β1 integrin activity via clickable isoxazoline-RGD-mimetics: development of molecular delivery systems 135
Expression of the transcription factor REST at different stages of neuronal differentiation: contribution of PKC and WNT/-catenin signaling 130
Molecular View on the iRGD Peptide Binding Mechanism: Implications for Integrin Activity and Selectivity Profiles 129
Inhibition of Toll-like Receptor 4 (TLR4)-induced NF-kB activation by NOP is lost in human glioblastoma cells chronically exposed to LPS. 129
Selective Integrin Ligands Promote Cell Internalization of the Antineoplastic Agent Fluorouracil 129
Peptidomimetic Scaffolds for the Discovery of New Bioactive Compounds. Cyclotetrapeptide Analogues Based on a 13-Membered, Partially Modified Retro-Inverso Structure. Applications to the synthesis of Cancer Cell Adhesion Inhibitors 128
Peptidomimetic probes for modulating α4β1 integrin activity 124
Editorial: Integrin Ligands and Their Bioconjugate Systems: Synthesis, Conformation, and Biological Activity 123
Targeting integrins with new beta-lactam derivatives 123
Dehydro-beta-amino acid containing peptidomimetics as integrin receptor ligands 121
Targeting integrins with new beta-lactam derivatives 115
Synthesis of new beta-lactam-based integrin ligands conjugated to cytotoxic agents 115
Targeting Integrins With New Beta-Lactam Derivatives 114
Design, synthesis and in vitro evaluation of tumor homing agents by conjugation of integrin ligands to diagnostics and cytotoxic drugs 113
Molecular Mechanisms Mediating Nociceptin/Orphanin FQ Receptor Signaling, Desensitization and Internalization. 113
Quantitative Systems Pharmacology and Biased Agonism at Opioid Receptors: A Potential Avenue for Improved Analgesics 113
Monitoring opioid receptor interaction in living cells by bioluminescence resonance energy transfer (bret) 112
Ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist, involves eosinophil's apoptosis. 108
Protein Kinase C-dependent up-regulation of human mu-opioid receptor gene (OPRM1) transcription is negatively influenced by the transcription factor REST 107
The ocular antiallergic action of mapracorat, a novel selective glucocorticoid receptor agonist, involves eosinophils and mast cells: evidence from human cells in vitro and an animal model 105
null 105
Monitoring opioid receptor dimerization in living cells by bioluminescence resonance energy transfer (BRET) 102
Novel Agonist Integrin Ligands: Synthesis, Biology & Applications 102
An in vitro assay to study the role of opioids in modulating immune cell adhesion 102
Genomic and non-genomic effects of anabolic steroids on opioid receptor gene expression in neuronal cells 101
Pro-inflammatory stimuli increase mu-opioid receptor (MOR) number on cell surface of human glioblastoma cells but hamper opioid agonist-induced intracellular signaling. G-protein-coupled-receptors: from structural insights to functional mechanisms 99
Novel Ligands Targeting alpha(4)beta(1) Integrin: Therapeutic Applications and Perspectives 98
PKC modulation of mu-opioid receptor gene (OPRM1) transcription is influenced by the transcription factor REST 97
TNF-alpha-induced MOR up-regulation in human glioblastoma cells is coupled to a loss of MOR-activated signalling to intracellular effectors 97
New βeta-lactam derivatives targeting RGD-binding and leukocyte integrins 97
Insulin-like Growth Factor I (IGF-I) modulates hMOR transcription in neuronal cells: role of STAT3 94
null 93
Experimental pharmacotherapy for dry eye disease: A review 93
New 4-aminoproline-based small molecule cyclopeptidomimetics as potential modulators of α4β1 integrin 93
SYNTHESIS OF NEW FLUORESCENT INTEGRIN AGONISTS WITH A BETA-LACTAM SCAFFOLD 92
Peripheral antinociceptive effects of the cyclic endomorphin-1 analog c[YpwFG] in a mouse visceral pain model 89
Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late phase experimental ocular allergy 82
Mesenchymal stem cell secretome to control inflammation in allergic conjunctivitis 79
Functional cross-talk between TLR4 and NOPr in human glial cells. 78
null 54
Evaluation of New β -Lactam Derivatives’ Effects on α4β1 and αMβ2 Leukocyte Integrin-Mediated Immune Cells Activation and Migration 53
Pharmacological characterization of selective α4β1 integrin antagonists 52
Targeting α4β1 integrin: from cyclic to linear ligands, effects of chemical modifications 52
α4β1 integrin targeting ligands for selective antineoplastic drug delivery in cancer cells 49
Leukocyte Integrins Targeting Ligands as an Innovative Therapeutic Approach for the Treatment of Inflammatory-based Diseases 45
Antifibrotic Efficacy of a Nintedanib–Peptide Conjugate and Diagnostic Potential of a Fluorescent Companion Probe Targeting αVβ6 Integrin in Idiopathic Pulmonary Fibrosis 38
Totale 13.767
Categoria #
all - tutte 35.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.571


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021341 0 0 0 0 0 0 0 0 0 43 99 199
2021/20221.581 134 80 102 64 151 88 54 195 73 104 231 305
2022/20231.808 165 289 93 237 119 162 91 91 368 39 100 54
2023/2024614 29 75 28 51 57 129 40 54 39 33 45 34
2024/20252.129 105 294 174 163 408 101 178 59 12 158 73 404
2025/20264.483 412 467 356 421 520 242 554 242 956 313 0 0
Totale 13.767